---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000062"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:06:40.164867+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lifecore amends ABL facility with FILO tranche; still faces Nasdaq delisting risk

## Summary
- Entered FILO tranche under ABL credit agreement with BMO; FILO loans bear SOFR +4.25%.
- Nasdaq Panel requested additional info on delayed filings; company responded May 10 and 14, 2024; no decision yet.
- Company continues to work to file delinquent periodic reports to regain Nasdaq Listing Rule 5250(c)(1) compliance.
- Repayments apply first to non-FILO, then FILO loans; FILO cap reduces monthly from October 2025.
- Seventh Amendment effective May 10, 2024; Loan Parties reaffirm obligations and release claims against lenders.

## SEC filing metadata
- accession: 0001005286-24-000062
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000062/0001005286-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000062/lndc-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000062
- JSON: https://secwatch.observer/filing/0001005286-24-000062.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000062.txt

## Key facts
- Material Agreements
  LIFECORE BIOMEDICAL, INC. DE amended Seventh Amendment to Credit Agreement with BMO Bank N.A. valued at Established FILO tranche of revolving loans with interest at SOFR plus 4.25%, monthly FILO Cap reduc (effective 2024-05-10).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: BMO Bank N.A.
  - Value: Established FILO tranche of revolving loans with interest at SOFR plus 4.25%, monthly FILO Cap reduc
  - Effective: 2024-05-10
  source text: On May 10, 2024, Lifecore Biomedical, Inc. (the “ Company ”), Curation Foods, Inc. (“ Curation ”) and Lifecore Biomedical Operating Company, Inc. (together with the Company and Curation, the “ Borrowers ”), and BMO Bank N.A. (f/k/a BMO Harris Bank N.A.) (“ BMO ”) entered into that certain Seventh Amendment to Credit Agreement (the “ FILO Amendment ”), which amended that certain Credit Agreement, dated as of December 31, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date of the FILO Amendment, the “ ABL Credit Agreement ” and the ABL Credit Agreement, as amended by the FILO Amendment, the “ Amended ABL Credit Agreement ”), by and among, inter alios, the Borrowers and BMO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000062/0001005286-24-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.